Fuller & Thaler Asset Management Inc. Has $872,000 Stock Position in Amgen Inc. $AMGN

Key Points

• Fuller & Thaler Asset Management Inc. significantly reduced its stake in Amgen Inc. by 92.4%, selling 34,173 shares and holding just 2,798 shares valued at $872,000 after the sale.
• Brighton Jones LLC and Pinebridge Investments L.P. increased their positions in Amgen by 23.5% and 250.6%, respectively, during the fourth quarter.
• Amgen announced a quarterly dividend of $2.38, which amounts to an annualized total of $9.52 and provides a dividend yield of 3.2%.

Fuller & Thaler Asset Management Inc. lowered its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 92.4% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,798 shares of the medical research company's stock after selling 34,173 shares during the period. Fuller & Thaler Asset Management Inc.'s holdings in Amgen were worth $872,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in AMGN. First Pacific Financial grew its holdings in Amgen by 304.5% during the 1st quarter. First Pacific Financial now owns 89 shares of the medical research company's stock valued at $28,000 after purchasing an additional 67 shares in the last quarter. Pinney & Scofield Inc. acquired a new stake in Amgen during the 4th quarter valued at $26,000. Global Wealth Strategies & Associates grew its holdings in Amgen by 1,388.9% during the 1st quarter. Global Wealth Strategies & Associates now owns 134 shares of the medical research company's stock valued at $42,000 after purchasing an additional 125 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in Amgen during the 4th quarter valued at $36,000. Finally, South Plains Financial Inc. acquired a new stake in Amgen during the 4th quarter valued at $37,000. Institutional investors and hedge funds own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have commented on AMGN. Bank of America increased their price objective on shares of Amgen from $252.00 to $261.00 and gave the company an "underperform" rating in a research note on Wednesday, July 23rd. Morgan Stanley increased their price objective on shares of Amgen from $330.00 to $333.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 6th. UBS Group reduced their price objective on shares of Amgen from $326.00 to $317.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 6th. Guggenheim began coverage on shares of Amgen in a research note on Tuesday, May 20th. They set a "neutral" rating and a $288.00 price objective on the stock. Finally, Wall Street Zen downgraded shares of Amgen from a "buy" rating to a "hold" rating in a research note on Saturday, August 9th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amgen currently has an average rating of "Hold" and a consensus price target of $303.76.

Amgen Stock Performance

Shares of Amgen stock traded down $2.04 during trading hours on Friday, reaching $293.72. The company's stock had a trading volume of 1,643,970 shares, compared to its average volume of 2,104,120. The company's 50 day simple moving average is $293.43 and its 200 day simple moving average is $293.17. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. Amgen Inc. has a one year low of $253.30 and a one year high of $339.17. The stock has a market cap of $158.13 billion, a P/E ratio of 24.02, a price-to-earnings-growth ratio of 2.53 and a beta of 0.49.

Amgen (NASDAQ:AMGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The medical research company reported $6.02 earnings per share for the quarter, topping analysts' consensus estimates of $5.28 by $0.74. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The business had revenue of $9.18 billion for the quarter, compared to analysts' expectations of $8.86 billion. During the same quarter last year, the company earned $4.97 EPS. The company's revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS. As a group, analysts expect that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, September 12th. Shareholders of record on Friday, August 22nd will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, August 22nd. This represents a $9.52 annualized dividend and a yield of 3.2%. Amgen's dividend payout ratio (DPR) is presently 77.84%.

Insider Activity

In other news, SVP Nancy A. Grygiel sold 1,267 shares of Amgen stock in a transaction that occurred on Wednesday, August 20th. The shares were sold at an average price of $296.99, for a total value of $376,286.33. Following the transaction, the senior vice president owned 7,209 shares of the company's stock, valued at $2,141,000.91. The trade was a 14.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, SVP Rachna Khosla sold 1,500 shares of the firm's stock in a transaction dated Thursday, June 5th. The stock was sold at an average price of $289.68, for a total transaction of $434,520.00. Following the completion of the transaction, the senior vice president owned 8,162 shares of the company's stock, valued at approximately $2,364,368.16. The trade was a 15.52% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.76% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.